91����

Robert “Bob” Hettich, an ORNL Corporate Fellow, is a pioneer in using mass spectrometry to uncover how microbes interact within complex environments and influence larger systems like plants and humans. A founder of the field of metaproteomics, he leads research that supports bioenergy, environmental resilience and health through advanced protein analysis.

Troy Carter, director of the Fusion Energy Division at 91����, leads efforts to make fusion energy a reality, overseeing key projects like MPEX and fostering public-private collaborations in fusion research. 

Scientists at ORNL have developed a method that can track chemical changes in molten salt in real time — helping to pave the way for the deployment of molten salt reactors for energy production.

US ITER has completed delivery of all components for the support structure of the central solenoid, the 60-foot-tall superconducting magnet that is the “heart” of the ITER fusion machine. 

During his first visit to 91����, Energy Secretary Chris Wright compared the urgency of the Lab’s World War II beginnings to today’s global race to lead in artificial intelligence, calling for a “Manhattan Project 2.”

Neus Domingo Marimon, leader of the Functional Atomic Force Microscopy group at the Center for Nanophase Materials Sciences of ORNL, has been elevated to senior member of the Institute of Electrical and Electronics Engineers.

P&G is using simulations on the ORNL Summit supercomputer to study how surfactants in cleaners cause eye irritation. By modeling the corneal epithelium, P&G aims to develop safer, concentrated cleaning products that meet performance and safety standards while supporting sustainability goals.

Scientists designing the world’s first controlled nuclear fusion power plant, ITER, needed to solve the problem of runaway electrons, negatively charged particles in the soup of matter in the plasma within the tokamak, the magnetic bottle intended to contain the massive energy produced. Simulations performed on Summit, the 200-petaflop supercomputer at ORNL, could offer the first step toward a solution.

Ryan Culler is the program manager at 91����, where he oversees the production of actinium-225, a promising treatment for cancer. Driven by a personal connection to cancer through his late brother, Culler is dedicated to advancing medical isotopes to help improve cancer care. 

Chad Parish, a senior researcher at ORNL, studies materials at the atomic level to improve nuclear reactors. His work focuses on fusion and fission energy, using microscopy and collaborating with experts to advance materials for extreme environments.